Cargando…

Survival Effects of Cytoreductive Surgery for Refractory Patients after Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer

PURPOSE: Salvage second-line chemotherapy is usually recommended for patients with advanced epithelial ovarian cancer (AEOC) who develop progressive disease (PD) after neoadjuvant chemotherapy (NAC). Herein, we investigated the role of cytoreductive surgery (CRS) for such patients. MATERIALS AND MET...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shin, Wonkyo, Noh, Joseph J., Seo, Sang-Soo, Kang, Sokbom, Choi, Chel-Hun, Park, Sang-Yoon, Kim, Byoung-Gie, Lim, Myong Cheol
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Yonsei University College of Medicine 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7593099/ https://www.ncbi.nlm.nih.gov/pubmed/33107236 http://dx.doi.org/10.3349/ymj.2020.61.11.935

Ejemplares similares

Survival outcomes after extensive cytoreductive surgery and selective neoadjuvant chemotherapy according to institutional criteria in bulky stage IIIC and IV epithelial ovarian cancer
por: Lim, Myong Cheol, et al.
Publicado: (2017)

The Knowledge and Attitude of Patients Diagnosed with Epithelial Ovarian Cancer towards Genetic Testing
por: Shin, Wonkyo, et al.
Publicado: (2021)

How to manage synchronous endometrial and ovarian cancer patients?
por: Shin, Wonkyo, et al.
Publicado: (2021)

Addendum: Shin, W.; et al. The Knowledge and Attitude of Patients Diagnosed with Epithelial Ovarian Cancer towards Genetic Testing. Int. J. Environ. Res. Public Health 2021, 18, 2312
por: Shin, Wonkyo, et al.
Publicado: (2021)

Feasibility of laparoscopic cytoreduction in patients with localized recurrent epithelial ovarian cancer
por: Paik, E Sun, et al.
Publicado: (2016)

The survival effect of ovary preservation in early stage endometrial cancer: a single institution retrospective analysis
por: Shin, Wonkyo, et al.
Publicado: (2020)

A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D
por: Lee, Jung-Yun, et al.
Publicado: (2019)

Uptake of Family-Specific Mutation Genetic Testing Among Relatives of Patients with Ovarian Cancer with BRCA1 or BRCA2 Mutation
por: Jeong, Go Woon, et al.
Publicado: (2021)

Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D
por: Park, Junsik, et al.
Publicado: (2023)

Interval between secondary cytoreductive surgery and adjuvant chemotherapy is not associated with survivals in patients with recurrent ovarian cancer
por: Jeong, Soo Young, et al.
Publicado: (2019)

Peritoneal cancer index in ovarian cancer
por: Shin, Wonkyo, et al.
Publicado: (2018)

Surgical outcomes of ureteral reconstruction during cytoreductive surgery for ovarian cancer: a retrospective cohort study
por: Kim, Ji Hyun, et al.
Publicado: (2022)

Incidence of epithelial ovarian cancer according to histologic subtypes in Korea, 1999 to 2012
por: Kim, Se Ik, et al.
Publicado: (2016)

Retrospective study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancer
por: Shin, Wonkyo, et al.
Publicado: (2018)

Prediction of a high-risk group based on postoperative nadir CA-125 levels in patients with advanced epithelial ovarian cancer
por: Kang, Sokbom, et al.
Publicado: (2011)

Completeness of pedigree and family cancer history for ovarian cancer patients
por: Son, Yedong, et al.
Publicado: (2014)

A predictive model based on site-specific risk factors of recurrence regions in endometrial cancer patients
por: Shin, Wonkyo, et al.
Publicado: (2022)

Feasibility and Safety of Extensive Upper Abdominal Surgery in Elderly Patients with Advanced Epithelial Ovarian Cancer
por: Lim, Myong Cheol, et al.
Publicado: (2010)

Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical Trial
por: Lim, Myong Cheol, et al.
Publicado: (2022)

Prognostic Factors for Advanced Epithelial Ovarian Cancer Following Primary Cytoreductive Surgery or Neoadjuvant Chemotherapy
por: Nantasupha, Chalaithorn, et al.
Publicado: (2022)

Lower extremity edema in patients with early ovarian cancer
por: Lim, Myong Cheol, et al.
Publicado: (2014)

Clinical implications of neoadjuvant chemotherapy in advanced endometrial cancer: a multi-center retrospective cohort study
por: Lim, Hyunji, et al.
Publicado: (2022)

The role of neoadjuvant chemotherapy in ovarian cancer patients with extensive tumor burden
por: Kang, Sokbom
Publicado: (2011)

Real-World Experience of Olaparib Maintenance in High-Grade Serous Recurrent Ovarian Cancer Patients with BRCA1/2 Mutation: A Korean Multicenter Study
por: Paik, E Sun, et al.
Publicado: (2019)

A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01)
por: Lee, Yong Jae, et al.
Publicado: (2021)

Quality of life outcomes from the randomized trial of hyperthermic intraperitoneal chemotherapy following cytoreductive surgery for primary ovarian cancer (KOV-HIPEC-01)
por: Kim, Ji Hyun, et al.
Publicado: (2022)

Phase II Study of Combination Chemotherapy with Etoposide and Ifosfamide in Patients with Heavily Pretreated Recurrent or Persistent Epithelial Ovarian Cancer
por: Kang, Heeseok, et al.
Publicado: (2009)

Incidence of venous thromboembolism after standard treatment in patients with epithelial ovarian cancer in Korea
por: Shin, Wonkyo, et al.
Publicado: (2021)

Improved Postoperative Pain Control for Cytoreductive Surgery in Women With Ovarian Cancer Using Patient-Controlled Epidural Analgesia
por: Oh, Tak Kyu, et al.
Publicado: (2016)

Prognostic significance of VEGF expression in patients with bulky cervical carcinoma undergoing neoadjuvant chemotherapy
por: Choi, Chel Hun, et al.
Publicado: (2008)

Incidence trends for epithelial peritoneal, ovarian, and fallopian tube cancer during 1999–2016: a retrospective study based on the Korean National Cancer Incidence Database
por: Shin, Wonkyo, et al.
Publicado: (2020)

Is Optimal Cytoreduction Post Neoadjuvant Chemotherapy the Only Prognostic Factor in Advanced Ovarian Cancer?
por: Dhiman, Pravesh, et al.
Publicado: (2022)

Is Optimal Cytoreduction Post Neoadjuvant Chemotherapy the Only Prognostic Factor in Advanced Ovarian Cancer?
por: Dhiman, Pravesh, et al.
Publicado: (2022)

Role of reactive thrombocytosis after primary cytoreductive surgery in advanced ovarian cancer
por: Kim, Myeong-Seon, et al.
Publicado: (2022)

Molecular Signature for Lymphatic Invasion Associated with Survival of Epithelial Ovarian Cancer
por: Paik, E Sun, et al.
Publicado: (2018)

Prevalence and clinical characterization of BRCA1 and BRCA2 mutations in Korean patients with epithelial ovarian cancer
por: Paik, E Sun, et al.
Publicado: (2021)

Health Behaviors and Associated Sociodemographic Factors in Cervical Cancer Survivors Compared with Matched Non-Cancer Controls
por: Park, Boyoung, et al.
Publicado: (2016)

Prognostic significance of normal-sized ovary in advanced serous epithelial ovarian cancer
por: Paik, E Sun, et al.
Publicado: (2018)

Critical Analysis of Stage IV Epithelial Ovarian Cancer Patients after Treatment with Neoadjuvant Chemotherapy followed by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC)
por: Munoz-Zuluaga, Carlos A., et al.
Publicado: (2020)

Incidence of cervical, endometrial, and ovarian cancer in Korea, 1999-2010
por: Lim, Myong Cheol, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ljtdpm8gig03tur1724sb74jhh